Article

APA House Call: Understanding Mentally Ill Mortality

Author(s):

How do comorbidities influence patients' life expectancies? What is the role of public health programs?

Oleguer Plana-Ripoll, PhD

Oleguer Plana-Ripoll, PhD

The 2020 American Psychiatric Association (APA) Annual Meeting was cancelled this year, with plans made to convert the world-leading psychiatry conference into a two-part virtual session and educational platform for attendees.

In lieu of regular on-site coverage, HCPLive® will be running a series of interviews, insights, and reporting on topics that frequently headline the APA meeting—featuring familiar experts.

New results from a Denmark-based population cohort assessment shows patients diagnosed with a mental disorder have had a slight increase in overall life expectancy from 1995-2015, as the rate of external causes of death—suicide, unintentional deaths—decreased in the population.

However, the findings also showed the same patients had a greater rate of natural deaths over time, meaning health-related issues have been playing a more significant role into what is now an approximate seven-year difference of life expectancy between someone with, and someone without, a mental illness.

In an interview with HCPLive®, research letter author by Oleguer Plana-Ripoll, PhD, of the National Center for Register-Based Research at Aarhus University, discussed the prevalence of comorbid conditions in patients with common mental disorders including depression. He also talked about the limitations of the register-based assessment, but the nonetheless evidenced trends of decades-long improvement that alludes to improved public health outreach for suicide and other health risk factors among patients with mental illnesses.

Plana-Ripoll also discussed the strain of common compounding factors in mental illness severity—from stigma to substance abuse—and how such issues could not be weighed in this cohort.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
© 2024 MJH Life Sciences

All rights reserved.